TheFly.com
MIST
Milestone Pharmaceuticals
$
()
Milestone: Etripamil 'effective' at restoring sinus rhythm in trial
Milestone Pharmaceuticals announces resubmission of NDA for etripamil
Milestone Pharmaceuticals reports FY23 EPS ($1.39), consensus ($1.37)
Milestone Pharmaceuticals 16.667M share Spot Secondary priced at $1.50
Milestone Pharmaceuticals announces offering of common stock, warrants
Milestone Pharmaceuticals announces plan to resubmit NDA for etripamil
Milestone Pharmaceuticals price target lowered by $8 at TD Cowen, here's why
Milestone Pharmaceuticals to resume trading at 7:30 am ET
Milestone Pharmaceuticals' etripamil spray New Drug Application refused by FDA
Milestone selloff on serious adverse event overdone, says H.C. Wainwright
Copyright ©1998-2024 Thefly.com LLC
